Treating hepatitis C infection by targeting the host

Translational Research

Volumn 159, Issue 6, 2012, Pages 421-429

  Salloum, Shadi ^a,b   Tai, Andrew W ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Ann Arbor Veterans Administration Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BOCEPREVIR; CALCINEURIN; CD81 ANTIGEN; CLAUDIN 1; DASATINIB; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; EPIDERMAL GROWTH FACTOR; ERLOTINIB; OCCLUDIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEINASE INHIBITOR; RAB PROTEIN; RAB7 PROTEIN; SCAVENGER RECEPTOR BI; TELAPREVIR; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; COXSACKIE VIRUS; CYTOPENIA; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM; FLU LIKE SYNDROME; HEPATITIS C; HOST; HUMAN; LIFE CYCLE; LIVER CELL CARCINOMA; MENTAL DISEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VIRUS ENTRY; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 84861646176     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2011.12.007     Document Type: Review

References (68)

1. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
2. M. Wise, S. Bialek, L. Finelli, B.P. Bell, and F. Sorvillo Changing trends in hepatitis C-related mortality in the United States, 1995-2004 Hepatology 47 2008 1128 1135
3. P. Simmonds, J. Bukh, and C. Combet Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 2005 962 973
4. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
5. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
6. H.W. Reesink, S. Zeuzem, and C.J. Weegink Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 131 2006 997 1002
7. C. Sarrazin, T.L. Kieffer, and D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
8. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
9. E.J. Gane, S.K. Roberts, and C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
10. H. Barth, E.K. Schnober, and F. Zhang Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction J Virol 80 2006 10579 10590
11. P. Pileri, Y. Uematsu, and S. Campagnoli Binding of hepatitis C virus to CD81 Science 282 1998 938 941
12. E. Scarselli, H. Ansuini, and R. Cerino The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus EMBO J 21 2002 5017 5025
13. M.J. Evans, T. von Hahn, and D.M. Tscherne Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801 805
14. A. Ploss, M.J. Evans, and V.A. Gaysinskaya Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Nature 457 2009 882 886
15. M.B. Zeisel, G. Koutsoudakis, and E.K. Schnober Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 Hepatology 46 2007 1722 1731
16. E. Blanchard, S. Belouzard, and L. Goueslain Hepatitis C virus entry depends on clathrin-mediated endocytosis J Virol 80 2006 6964 6972
17. D. Egger, B. Wölk, and R. Gosert Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex J Virol 76 2002 5974 5984
18. J. Mackenzie Wrapping things up about virus RNA replication Traffic 6 2005 967 977
19. D. Paul, I. Romero-Brey, and J. Gouttenoire NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional HCV replication complexes J Virol 85 2011 6963 6976
20. G. Barba, F. Harper, and T. Harada Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets Proc Natl Acad Sci U S A 94 1997 1200 1205
21. Y. Miyanari, K. Atsuzawa, and N. Usuda The lipid droplet is an important organelle for hepatitis C virus production Nat Cell Biol 9 2007 1089 1097
22. S. Boulant, P. Targett-Adams, and J. McLauchlan Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus J Gen Virol 88 2007 2204 2213
23. H. Huang, F. Sun, and D.M. Owen Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins Proc Natl Acad Sci U S A 104 2007 5848 5853
24. P. Gastaminza, G. Cheng, and S. Wieland Cellular determinants of hepatitis C virus assembly, maturation, degradation and secretion J Virol 82 2008 2120 2129
25. W.J. Benga, S.E. Krieger, and M. Dimitrova Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles Hepatology 51 2010 43 53
26. W. Cun, J. Jiang, and G. Luo The C-terminal alpha-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virus J Virol 84 2010 11532 11541
27. J. Jiang, and G. Luo Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles J Virol 83 2009 12680 12691
28. K.S. Chang, J. Jiang, Z. Cai, and G. Luo Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture J Virol 81 2007 13783 13793
29. A. Pfannkuche, K. Büther, and J. Karthe C-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: a prerequisite for replication Hepatology 53 2011 1127 1136
30. F. Yang, J.M. Robotham, and H.B. Nelson Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro J Virol 82 2008 5269 5278
31. A. Kaul, S. Stauffer, and C. Berger Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
32. L. Coelmont, X. Hanoulle, and U. Chatterji DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS ONE 5 2010 e13687
33. E. Herker, C. Harris, and C. Hernandez Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1 Nat Med 16 2010 1295 1298
34. J. Lupberger, M.B. Zeisel, and F. Xiao EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 17 2011 589 595
35. Z. Zhang, D. Harris, and V.N. Pandey The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus J Virol 82 2008 5761 5773
36. T. Okamoto, Y. Nishimura, and T. Ichimura Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90 EMBO J 25 2006 5015 5025
37. S. Taguwa, T. Okamoto, and T. Abe Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication J Virol 82 2008 2631 2641
38. Y. Amako, A. Sarkeshik, H. Hotta, J. Yates 3rd, and A. Siddiqui Role of oxysterol binding protein in hepatitis C virus infection J Virol 83 2009 9237 9246
39. Y. Amako, G.H. Syed, and A. Siddiqui Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein J Biol Chem 286 2011 11265 11274
40. A.W. Tai, Y. Benita, and L.F. Peng A functional genomic screen identifies cellular cofactors of hepatitis C virus replication Cell Host Microbe 5 2009 298 307
41. Q. Li, A.L. Brass, and A. Ng A genome-wide genetic screen for host factors required for hepatitis C virus propagation Proc Natl Acad Sci U S A 106 2009 16410 16415
42. M. Trotard, C. Lepère-Douard, and M. Régeard Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening FASEB J 23 2009 3780 3789
43. F.H. Vaillancourt, L. Pilote, and M. Cartier Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication Virology 387 2009 5 10
44. J. Borawski, P. Troke, and X. Puyang Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication J Virol 83 2009 10058 10074
45. K.L. Berger, J.D. Cooper, and N.S. Heaton Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication Proc Natl Acad Sci U S A 106 2009 7577 7582
46. S. Reiss, I. Rebhan, and P. Backes Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment Cell Host Microbe 9 2011 32 45
47. M. Stone, S. Jia, W. Do Heo, T. Meyer, and K.V. Konan Participation of Rab5, an early endosome protein, in hepatitis C virus RNA replication machinery J Virol 81 2007 4551 4563
48. E.H. Sklan, R.L. Serrano, and S. Einav TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication J Biol Chem 282 2007 36354 36361
49. E.H. Sklan, K. Staschke, and T.M. Oakes A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication J Virol 81 2007 11096 11105
50. I. Hamamoto, Y. Nishimura, and T. Okamoto Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B J Virol 79 2005 13473 13482
51. L. Gao, H. Aizaki, J.W. He, and M.M. Lai Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft J Virol 78 2004 3480 3488
52. D.F. Mercer, D.E. Schiller, and J.F. Elliott Hepatitis C virus replication in mice with chimeric human livers Nat Med 7 2001 927 933
53. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
54. S. Ciesek, E. Steinmann, and H. Wedemeyer Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A Hepatology 50 2009 1638 1645
55. K. Watashi, N. Ishii, and M. Hijikata Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase Mol Cell 19 2005 111 122
56. Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J Virol 83 2009 6554 6565
57. F. Yang, J.M. Robotham, and H. Grise A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach PLoS Pathog 6 2010 e1001118
58. X. Puyang, D.L. Poulin, and J.E. Mathy Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors Antimicrob Agents Chemother 54 2010 1981 1987
59. F. Fernandes, I.U. Ansari, and R. Striker Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A PLoS ONE 5 2010 e9815
60. T.L. Foster, P. Gallay, N.J. Stonehouse, and M. Harris Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 85 2011 7460 7464
61. J. Paeshuyse, A. Kaul, and E. De Clercq The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
62. L. Coelmont, S. Kaptein, and J. Paeshuyse Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2008 967 976
63. R. Flisiak, S.V. Feinman, and M. Jablkowski The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients Hepatology 49 2009 1460 1468
64. Flisiak R, Pawlotsky JM, Crabbé R, et al. Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany 2011. p. Abstract 190.
65. N.Y. Hsu, O. Ilnytska, and G. Belov Viral reorganization of the secretory pathway generates distinct organelles for RNA replication Cell 141 2010 799 811
66. S.J. Smith, S. Cases, and D.R. Jensen Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat Nat Genet 25 2000 87 90
67. A.M. Birch, L.K. Buckett, and A.V. Turnbull DGAT1 inhibitors as anti-obesity and anti-diabetic agents Curr Opin Drug Discov Devel 13 2010 489 496
68. Y. Nahmias, J. Goldwasser, and M. Casali Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin Hepatology 47 2008 1437 1445